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Abstract
Inflammation is one underlying contributing factor in the pathology of acute and chronic kidney disorders.
Phagocytes such as monocytes, neutrophils and dendritic cells are considered to play a deleterious role in
the progression of kidney disease but may also contribute to organ homeostasis. The kidney is a target of
life-threatening autoimmune disorders such as the antineutrophil cytoplasmic antibody (ANCA)-associated
vasculitides (AAV). Neutrophils and monocytes express ANCA antigens and play an important role in the
pathogenesis of AAV. Noninvasive in vivo methods that can quantify the distribution of inflammatory cells
in the kidney as well as other organs in vivo would be vital to identify the causality and significance of
inflammation during disease progression. Here we describe an noninvasive technique to study renal
inflammation in rodents in vivo using fluorine (19F) MRI. In this protocol we chose a murine ANCA-
AAV model of renal inflammation and made use of nanoparticles prepared from perfluoro-5-crown-15-
ether (PFCE) for renal 19F MRI.
This chapter is based upon work from the COST Action PARENCHIMA, a community-driven network
funded by the European Cooperation in Science and Technology (COST) program of the European Union,
which aims to improve the reproducibility and standardization of renal MRI biomarkers. This experimental
protocol chapter is complemented by two separate chapters describing the basic concept and data analysis.
Key words Magnetic resonance imaging (MRI), Fluorine (19F), Nanoparticles (NPs), Inflammation,
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1 Introduction
Inflammation is one underlying contributing factor in the pathol-
ogy of acute and chronic kidney disorders [1]. Studies also suggest
that systemic inflammation can cause ischemic injury in a vital
organ, such as the kidney, which could then result in repercussions
in another distant organ downstream of the ischemic event, such as
the heart [2–4]. Early inflammatory events governed by cells of the
innate immune system, such as macrophages, probably promote
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renal tissue injury but may also support repair [5–8]. Phagocytes
such as dendritic cells (DC) andmacrophages are considered to play
a deleterious role in the inflammatory outcome of chronic kidney
disease but may also contribute to organ homeostasis [9].
The kidney is often a target of systemic autoimmune disorders
that are compounded by complex inflammatory processes
[10]. Examples of life-threatening autoimmune disorders that affect
the kidneys are the antineutrophil cytoplasmic antibody (ANCA)-
associated vasculitides (AAV) manifesting as rapidly progressive nec-
rotizing crescentic glomerulonephritis (NCGN) [11]. Neutrophils
and monocytes express ANCA antigens and ANCA induces neutro-
phil extracellular traps that cause RIPK1-dependent endothelial cell
(EC) damage via activation of the alternative complement pathway
[12]. While the central role of neutrophil activation in ANCA-
associated vasculitis and NCGN is clear, the role of monocytes/
macrophages was only recently uncovered in a renal ANCA-
associated vasculitis model [13].
Noninvasive in vivo methods that can quantify the level of
inflammation in the kidney as well as other organs in system autoim-
mune disorders such as ANCA-associated vasculitides would be vital
to identify the causality and significance of inflammation during the
course of disease. One method to visualize inflammation by MRI
makes use of MR contrast agents that modulate T2
* and that are
easily taken up by phagocytic inflammatory cells [14, 15]. Iron oxide
particles including ultrasmall iron oxide agents (USPIO) have been
used as susceptibility (T2
*) MR contrast agents to target inflamma-
tory cell populations. These particles are engulfed by phagocytic cells
in the blood. Drawbacks of USPIO-based T2
* studies include MR
signal quantification and difficulty to distinguish contrast created by
labeled cells from other intrinsic tissue contrasts [14].
Here we describe an alternative noninvasive technique to study
inflammation in rodents in vivo using fluorine (19F) MRI. 19F MRI
is performed in association with intravenous injections of perfluo-
rocarbon (PFC) nanoparticles (NPs). These NPs are taken up by
cells of the immune system traveling through the circulation into
the inflammatory regions. Thus 19F MRI is ideal for studying
distribution of inflammatory cell in vivo. In this protocol we
chose a murine AAV model of renal inflammation that has been
described in greater depth elsewhere [16] and made use of nano-
particles prepared from perfluoro-5-crown-15-ether (PFCE).
This experimental protocol chapter is complemented by two
separate chapters describing the basic concept (please see the chapter
by Waiczies S et al. “Functional Imaging Using Fluorine (19F) MR
Methods: Basic Concepts”) and data analysis (please see the chapter
by Starke L et al. “Data Preparation Protocol for Low Signal-to-
Noise Ratio Fluorine-19 MRI”), which are both part of this book.
This chapter is part of the book Pohlmann A, Niendorf T (eds)
(2020) Preclinical MRI of the Kidney—Methods and Protocols.
Springer, New York.
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2 Materials
2.1 Animals This experimental protocol is tailored for mice with a body mass of
20-30 g (e.g., wild type C57BL/6 mice or a disease model of renal
inflammation). Here we describe briefly how to generate the AAV
animal model. More thorough detail on the immunization, bone
marrow transplantation as well purification of mouse MPO is given
in the study establishing the MPO-AAV animal model
[16]. Wild-type (WT) C57BL/6J mice (B6) (Jackson Laboratories,
Bar Harbor, ME) and myeloperoxidase-deficient (MPO/) mice
(generated by Aratani et al. [17]) were used in this protocol.
MPO/ mice were immunized with murine MPO at the age of
8–10 weeks, subjected to lethal irradiation, and then transplanted
with MPO-expressing bone marrow cells. Animal experiments
should be approved by animal welfare authorities and guidelines
to minimize discomfort to animals (86/609/EEC).
2.1.1 Lab Equipment 1. NP preparation: Ultrasonic device with ultrasonic power
(400W) and frequency (24 kHz) for stand-mounted operation
such as UP400S (Hielscher, Teltow, Germany) to prepare
PFCE nanoparticles.
2. NP preparation: Titanium sonotrode for emulsifying samples
from 5 to 200 ml (e.g., H3 from Hielscher, Teltow, Germany).
3. NP characterization: Dynamic light scattering instrument such
as Zetasizer Nano (Malvern Instruments, Malvern, Worcester-
shire, UK) to characterize particle size (Z-average) and poly-
dispersity index (PDI) of the PFCE nanoparticles.
4. NP application: Mouse restrainer for intravenous administer-
ing the PFCE nanoparticles.
5. Anesthesia: Isoflurane inhalation system which can adjust dif-
ferent levels of isoflurane such as Isoflurane Vapor 19.1 (Drae-
ger, Draegerwerk, Luebeck, Germany). The range of isoflurane
level that is used for anesthesia in mice is 0.5–1.5%. Please refer
to the chapter by Kaucsar T et al. “Preparation and Monitoring
of Small Animals in Renal MRI” for an in-depth description
and discussion of the anesthesia.
6. Anesthesia: Mouse chamber connected to isoflurane inhalation
system and gas-mixing system to anesthetize mice by inhalation
narcosis prior to transfer to the MR scanner.
7. Gases: O2, and compressed air, as well as a gas-mixing system
such as FMI (Föhr Medical Instruments GmbH, Seeheim-
Ober Beerbach, Germany) to achieve the required physiologi-
cal O2/air mixture in combination with the isoflurane gas.
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2.2 MRI Hardware The general hardware requirements for renal 1H MRI on mice and
rats are described in the chapter by Ramos Delgado P et al. “Hard-
ware Considerations for Preclinical Magnetic Resonance of the
Kidney.” The technique described in this chapter was tailored for
a 9.4 T MR system (Biospec 94/20, Bruker Biospin, Ettlingen,
Germany) but advice for adaptation to other field strengths is given
where necessary.
1. 1H/19F dual-tunable volume RF coil (35 mm inner diameter,
50 mm length; Rapid Biomed, Würzburg, Germany).
2. 1H/19F dual-tunable volume RF coil (18 mm inner diameter,
39 mm length) for ex vivo imaging [18].
3. 19F cryogenic quadrature RF surface probe (19F-CRP) oper-
ated at ~28 K (see Note 1).
4. A physiological monitoring system that can track respiration
and temperature during the MR procedure such as the Moni-
toring & Gating System and PC-sam software from SA Instru-
ments (SAII, Stony Brook, NY, USA).
5. Mouse sled with a breathing mask connected to the isoflurane
system.
2.3 MRI Techniques Typically, 19F MR studies applying PFC compounds such as PFCE
to study inflammation in vivo employ the turbo spin echo
(SE) rapid acquisition using relaxation enhancement (RARE)
sequence [18–22]. This method reduces acquisition time by accu-
mulating multiple echoes within a single repetition time [23]. Typi-
cally T1 of these
19F compounds is in the range of 0.5–3 s,
depending on the compound and also magnetic field strength
(B0). However, if employing paramagnetic macrocyclic PFC com-
pounds complexed to lanthanides, T1 values can be reduced to the
order of 1–15 ms and T2* values correspondingly reduced to
0.4–12 ms and a radial zero echo time (ZTE) sequence might be
better suited [24].
1. 1H MR sequence: 2D and 3D FLASH protocols are standard
sequences on Bruker MRI systems, where they are called
“FLASH_2D”, “FLASH_3D” or “1_Localizer_multi_slice”
(see Note 2).
2. 19F spectroscopy sequence: Block pulse for nonlocalized (global)
is a standard sequence on Bruker MRI systems, where it is
called “SINGLEPULSE” (see Note 3).
3. 19F MR sequence: 3D RARE protocol for measurements. This is
a standard sequence on Bruker MRI systems, where it is called
“TurboRARE_3D” in Paravision 5, “T2_TurboRARE_3D” in
Paravision 6 (see Note 4).
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3 Methods
3.1 MR
Protocol Setup
3.1.1 19F MR Imaging
Typically T1 of PFC compounds is in the range of 0.5–3 s, depend-
ing on the compound and also magnetic field strength (B0). When
working with a standard diamagnetic PFC such as PFCE that is
documented in the literature, it is recommended that the T1 and T2
of the compound be studied at 37 C before starting with the first
in vivo experiments to study inflammation. According to the
measured relaxation times (T1/T2), the optimal settings for
RARE, namely echo train lengths (ETL) and repetition time
(TR) should be calculated to improve sensitivity thresholds.
1. Repetition time (TR): for RARE, TR will be limited by ETL
and the number of slices. A short TR is desirable for SNR
efficiency (0.8–1.5 s depending on T1) keeping in mind that
T1 will change with changes in oxygenation status (seeNote 5).
2. Flip angle (FA): for the block pulse and RARE sequence, the
FA for the excitation pulse should be at 90. Additionally the
RARE sequence has a refocusing pulse with a FA of 180. To
maximize the SNR and contrast, the flip angle has to be sepa-
rately calculated for FLASH considering the Ernst angle:
αE ¼ cos 1 eTR=T 1
 
which relates FA, T1 and TR (see Note
6).
3. Echo train length (ETL): in RARE, use a value as high as
possible to reduce scan time. In the TurboRARE sequence on
Bruker MRI systems, ETL is referred to as “rare factor”.
4. Echo time (TE): use the shortest effective TE and echo spacing
(ΔTE) possible. Especially for very high ETL, TE can become
very long. Centric encoding can be used to reduce the effective
TE, generally at the cost of introducing minor image artifacts.
5. Acquisition bandwidth (BW): long enough to shorten the ΔTE
without compromising the SNR, which decreases with increas-
ing BW as a result of increased noise level.
6. Geometry: Adapt so that whole abdomen fits into FOV in L-R
direction (approx. 25 mm for mice) and use frequency encod-
ing in H-F- direction. Choose a 3D volume suited to cover the
whole body width and as much of the length of the mouse that
the RF coil can afford as possible. With a typical mouse body
resonator as the one used in this protocol one could use a FOV
of 60  30  30 mm and matrix size of 400  200  200 (for
1H) and 128  64  64 (for 19F).
7. Resolution/acceleration: Use the highest in-plane resolution
that the SNR allows, typically around 100–150 μm for 1H
MR scans and 250–500 μm for 19F MR scans. Zero-filling in
phase encoding direction can be helpful to speed up acquisition
while increasing the number of averages to improve SNR
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especially for 19F MR scans. One may use half Fourier in read
direction (asymmetric echo) to further shorten the first
TE. Reducing the excitation pulse length to below 1 ms
would then also help to shorten TE.
8. For an example of parameters used in this chapter, please see
Notes 7 and 13.
3.2 19F Nanoparticle
Preparation,
Characterization,
and Application
1. NP preparation: Emulsify 1.2 M PFCE (Fluorochem, Derby-
shire, UK) in Pluronic F-68 (Sigma-Aldrich, Germany) for
10 min using a cell disrupting titanium sonotrode connected
to an ultrasonic device and employing a continuous pulse
program for 60 s. Use ear protection while sonicating the
mixture to avoid hearing damage and loss.
2. NP characterization: Measure mean particle size (in nm), poly-
dispersity index (PdI), and zetapotential (mV) by using a
dynamic light scattering machine such as the one listed above.
Use the z-average diameter for particle size since it gives an
intensity-weighted harmonic diameter and is ideal for compar-
ing different analyses. The nanoparticles should have a
PdI < 0.3 indicating a relatively low polydispersity and narrow
size distribution (see Note 8).
3. NP application: Administer 19F nanoparticles via tail vein at a
dose of 5–80 μmol of PFCE molecules, depending on the
frequency of the bolus injections. Start administering 19F nano-
particles at relevant time-points of your inflammatory model,
for example, in MPO immunized MPO/ mice subjected to
lethal irradiation we started intravenous application of PFCE
nanoparticles 4–8 weeks following transplantation of
MPO-expressing bone marrow cells (see Note 9).
3.3 Preparation Prior
to 19F/1H MRI Scans
Four to 18 h following the last intravenous administration of 19F
nanoparticles prepare the mice for 19F/1H MRI:
1. First anesthetize the mice by inhalation narcosis using a mouse
chamber connected to a isoflurane inhalation system and
gas-mixing system (see Note 10).
2. Adjust the flow rate for air and O2 at 0.2 and 0.1 l/min
respectively and 3% isoflurane (adjusted from a vaporizer) for
about 2 min until the required level of anesthesia is reached
(no response following toe pinch).
3. Transfer mice to the MR scanner. Should a quantification of
inflammation be required, a reference tube with a known con-
centration of 19F nanoparticles should be placed in proximity
to the region of interest. For quantification of signal please
refer to the chapter by Starke L et al. “Data Preparation
Protocol for Low Signal-to-Noise Ratio Fluorine-19 MRI.”
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4. While keeping the flow rate for air and O2 constant, adjust the
isoflurane vaporizer to 0.8–1.5% until an optimal breathing
pattern is reached.
5. Set up the temperature monitoring (rectal probe) and respira-
tory monitoring (balloon on chest) unit. A respiratory rate of
70–90 breaths per minute is recommended. Keep the body
temperature at 36–37 C during the experiment by employing
a warm water (or alternatively warm air) circulation system.
6. Tune the RF coil to both the 1H resonance frequency (e.g.,
400.1 MHz for 9.4 T) and to the 19F resonance frequency
(e.g., 376.3 MHz for 9.4 T) and match the characteristic
impedance of the coil to 50 Ω using the tuning monitor of
the animal MR scanner.
7. Perform anatomical imaging as described in the chapter by
Pohlmann A et al. “Essential Practical Steps for MRI of the
Kidney in Experimental Research.” Set up a 2D FLASH proto-
col for the acquisition of anatomical kidney 1H scans (see Note
7).
8. Perform localized shimming on the kidney imaging as
described in the chapter by Pohlmann A et al. “Essential Prac-
tical Steps for MRI of the Kidney in Experimental Research”
(see Note 11).
9. Save the parameters of all adjustments (such as iterative shim-
ming calculations and reference power values) performed dur-
ing the first 1H scans for application into the 19F scans.
3.4 19F/1H MRI
of the Kidney
3.4.1 In Vivo 19F/1H MRI
Using a Room Temperature
Mouse Body Volume 19F/1H
RF Resonator
Following acquisition of the anatomical 1H kidney scans, in vivo
19F MR images of the kidney can be acquired and later overlaid
onto the 1H MR images. An example of an in vivo 1H/19F MRI is
shown in Fig. 1.
1. Load the SINGLEPULSE FID-sequence with a TR of at least
1000 ms.
2. Set nucleus to 19F (e.g., in “Open Edit Scan” in Bruker’s
Paravision 5.1 or “System” tab in Bruker’s Paravision 6).
Since the 19F MR signal is too low for automatic adjustments,
apply the same settings used for the 1H anatomical scans (see
Note 12).
3. Deselect the automatic reference gain (RG) and set on maxi-
mum (e.g., in Edit Method in Bruker’s Paravision 5.1 or using
the “Instruction” tab (GOP) and “Setup” tab in Paravision 6).
4. Start the SINGLEPULSE sequence using setup mode. If the
19F spectral signal within the acquisition-window is too low,
add more averages until a signal is clearly visible. Adjust the
basic frequency in order to center the 19F spectral peak at 0 Hz
in the acquisition window. Apply this basic frequency, press
Stop and apply.
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5. Setup a TurboRARE 3D protocol for the 19F scans.
6. Use the same geometry used for anatomical 1H imaging but
reduce the matrix size for increased SNR and use a rare factor of
at least 32. Set nucleus to 19F. Deselect automatic adjustments
(as above). For an example of parameters, please see Note 7.
7. When the scans are finished retract the mouse-holder from the
MR scanner. Disconnect the mouse carefully from the holder.
If the mouse is not sacrificed for ex vivo analysis (e.g., high
resolution 19FMRI of the kidney, see below) following the MR
scans, closely monitor until it has completely recovered from
anesthesia. Body temperature regulation might still be affected
after the anesthesia, so during the recovery process, put the
mouse in a separate cage that is placed on a warm temperature
regulated pad. Once the mouse has completely recovered from
anesthesia, you may return it to its holding cage and to the
animal room.
3.4.2 High Spatial
Resolution 19F MRI of Ex
Vivo Kidney Using a 19F
CryoProbe
Kidney inflammation can also be studied with high spatial resolu-
tion ex vivo 19F MRI, for example, by using a transceive 19F
CryoProbe, which we previously used to study brain inflammation
in a model of CNS autoimmunity [25]. An example of a high
resolved ex vivo 1H/19F MRI of the kidney is shown in Fig. 2.
1. At the end of the in vivo experiment, anesthetize mice with a
terminal dose of ketamine and xylazine. Ensure the required
level of anesthesia is reached (no response following toe pinch).
2. Transcardially perfuse mouse with 20 ml PBS followed by
20 ml 4% paraformaldehyde.
Fig. 1 In vivo 19F/1H MRI of a murine ANCA-AAV model of renal inflammation using the 1H/19F dual-tunable
volume RF coil (35 mm inner diameter). Eight weeks following transplantation of bone marrow cells, MPO-AAV
mice were administered one bolus of PFCE nanoparticles (NPs) intravenously (80 μmol in 100 μl) and 19F/1H
MRI was performed 4 h (a) and 12 h (b) thereafter. (1) 1H 2D FLASH protocol: TR ¼ 579.4 ms, TE ¼ 5 ms,
FA ¼ 75, matrix ¼ 256  128. (2) 19F 3D RARE protocol: TR ¼ 800 ms, TE ¼ 6.16 ms,
Matrix ¼ 256  128  128, RARE Factor ¼ 32
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3. Harvest relevant organs (e.g., kidney, liver, and spleen).
4. Transfer organs to a container filled with 4% PFA and store at
4 C.
5. Prior to the high resolution 19F MRI of the kidney, embed the
kidney in 1% low melting agarose in a 1.5 ml Eppendorf tube.
6. 19F-CRP adjustments: since the 19F signal is too low for auto-
matic adjustments, use a 19F calibration phantom (fill highly
fluorinated substance such as trifluoroethanol with water in a
1.5 ml Eppendorf tube. Place the 19F calibration tube under
the 19F-CRP and repeat steps 13–16 to calculate the working
frequency. Load and run a 1_Localizer_multi_slice sequence
(see above). Adjust the reference power using the adjustments
platform: select a coronal slice of 2 mm thickness and place it
close to the RF coil’s surface. Select an initial power two orders
of magnitude smaller than what is usually expected and press
start. Run the rest of the adjustments using the same sequence.
Save the shim settings.
7. 19F-CRP imaging: place the ex vivo kidney embedded in a
1.5 ml Eppendorf tube under the 19F-CRP surface. Run the
working frequency adjustments as per 13–16, load the shim
Fig. 2 Ex vivo 19F/1H MRI of an inflamed kidney from the ANCA-AAV model. (a) Low spatial resolution images
acquired using the 1H/19F dual-tunable volume RF coil (18 mm inner diameter). At this resolution
[0.938  0.938]mm2, a high 19F signal can be achieved already after 1 h acquisition time. However,
anatomical detail is lacking in the 19F MR images. (b) High spatial resolution images acquired with the 19F
cryogenic quadrature RF surface probe (19F-CRP). The gain in SNR achieved by the 19F-CRP was used to
increase the in plane spatial resolution [0.078  0.078]mm2
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calculations, and adjust the reference power as described above.
Set the RG to maximum. Load a 2D FLASH protocol and set it
up for 19F imaging. Examples for high and medium resolution
19F imaging are given in Note 13.
8. Set up a 2D FLASH protocol for the acquisition of anatomical
kidney 1H scans. Use the same geometry used for 19F imaging
(see Note 13).
4 Notes
1. The transceive 19F cryogenic quadrature RF surface probe (19F
CryoProbe) operates at ~28 K with a dual cooled preamplifier
at the base running at ~77 K. It has a similar geometry to the
existing Bruker 1H quadrature CryoProbes. More details on
the 19F CryoProbe are available in our previous study [25].
2. The FLASH_3D protocol is especially adapted for whole-body
imaging of mice (the gradient-system and the volume-
resonator need to have a linear region of about 8 cm).
3. The block pulse program (SINGLEPULSE) contains the nec-
essary elements for a simple transmit/receive experiment,
sending a pulse and acquiring an FID afterward.
4. A 2D version of this sequence is also available, which allows
thicker slices for a general overview but suffers from low SNR
for most in vivo applications.
5. Special attention should be given when studying inflammation
in models where tissue oxygen levels are likely to change, for
example, following ischemic events. In these cases, T1 weight-
ing needs to be reduced at cost of SNR efficiency by increasing
TR T1 (typically TR ¼ 3–5  T1).
6. When using transmit-receive surface coils a B1 correction
should be considered in order to compensate for the intrinsic
spatial gradient in coil sensitivity (B1
) and excitation field (B1
+
inhomogeneity), which results is signification variation in the
excitation FA, decreasing with increasing distance from the RF
coil surface. This severely reduces image homogeneity and
hampers the acquisition of the absolute signal intensity values
for 19F quantification techniques.
7. Example for a 30 g mouse at 9.4 T and FOV of
50  25  25 mm, (1) 1H 2D FLASH protocol:
TR ¼ 579.4 ms, TE ¼ 5 ms, FA ¼ 75, matrix ¼ 256  128.
(2) 19F 3D RARE protocol: TR ¼ 800 ms, TE ¼ 6.16 ms,
Matrix ¼ 256  128  128, RARE Factor ¼ 32–64.
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8. The polydispersity index (PdI) is extrapolated from the DLS
function and quantitatively describes the particle size distribu-
tion best. PdI ranges from 0.01 for monodispersed particles to
0.7 for particles that have a very broad size distribution. The z-
average diameter gives the mean diameter based on intensity of
scattered light and sensitive to presence of large particles, peak
diameter, peak width, and PdI.
9. In MPO-AAV mice we administered one bolus of PFCE nano-
particles intravenously (80 μmol in 100 μl) 8 weeks following
transplantation of bone marrow cells.
10. Mice can be alternatively anesthetized with an intraperitoneal
injection of ketamine and xylazine.
11. Shimming is particularly important, since macroscopic mag-
netic field inhomogeneities affect the exact resonance fre-
quency of the PFCE compounds and might affect
quantification of the 19F MR signal. Shimming should be
performed on a voxel enclosing both kidneys using either the
default iterative shimming method or the Mapshim technique
(recommended). However, the Mapshim technique is not
available for X-nuclei-only RF coils. An alternative in this case
is to use a highly fluorinated sample to calculate the shims.
12. Since the NMR properties of 19F and 1H are similar, the same
MR setup and MR parameter settings can be used for both
nuclei.
13. Example for ex vivo high-resolved 19F MRI at 9.4 T using the
19F-CRP and a 2D FLASH: TR ¼ 11 ms, TE ¼ 2.7 ms,
FA ¼ 30, Avg ¼ 2250, Repetitions ¼ 35, FOV ¼ 20  20,
matrix¼ 256 256, 1 mm slice thickness. Example for ex vivo
low-resolved 19F MRI at 9.4 T using the 1H/19F dual-tunable
volume RF coil (18 mm inner diameter) and a 3D RARE
method: TR ¼ 800 ms, TE ¼ 5 ms, Avg ¼ 256, Repeti-
tions ¼ 13, FOV ¼ 60  30  30, matrix ¼ 64  32  16.
1H 2D FLASH protocol: TR ¼ 18.7 ms, TE ¼ 5.5 ms,
FA ¼ 25, matrix ¼ 171  256, 1 mm slice thickness.
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